Will India be First Country to Revoke Marketing Licenses for HPV Vaccines?
A petition currently before the Supreme Court of India alleges that the Drugs Controller of India issued licenses for Gardasil and Cervarix without adequate research on safety as directed by the Parliamentary Standing Committee on Health and Family Welfare. Petition number 558/2012, filed by Kalpana Mehta, Nalini Bhanot and V. Rukmini Rao, seeks to resolve this and several other issues by asking the Supreme Court of India to rescind the licenses for marketing and administration of HPV vaccines, make provisions to identify and treat any girls left with chronic health problems and/or autoimmune disorders after their participation in HPV vaccine trials, blacklist the Program for Appropriate Technology in Health (PATH), and allow no other foreign agencies to have a field presence in India. Will India be the first country in the world to revoke the marketing licenses for Gardasil and Cervarix? Will the Supreme Court of India move to protect the health and welfare of their young citizens, or the interests of the HPV vaccine manufacturers? Will PATH and similar agencies be banned from operating in India? Will the victims of adverse reactions to HPV vaccines be located and treated? We can only hope these questions will be answered when the final hearing will take place.





















